$3.74
12.31% yesterday
Nasdaq, Dec 04, 10:00 pm CET
ISIN
US6033801068
Symbol
NERV

Minerva Neurosciences Inc Stock price

$3.74
+0.07 1.91% 1M
+1.89 102.16% 6M
+1.52 68.35% YTD
+1.55 70.78% 1Y
+0.42 12.65% 3Y
-18.18 82.94% 5Y
-33.94 90.07% 10Y
-44.66 92.27% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
+0.41 12.31%
ISIN
US6033801068
Symbol
NERV
Industry

Key metrics

Basic
Market capitalization
$23.3m
Enterprise Value
$71.0m
Net debt
$47.7m
Cash
$12.3m
Shares outstanding
7.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-69.2%
Return on Equity
-5.6%
ROCE
-57.6%
ROIC
-
Debt/Equity
-1.7
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-14.6m | -
EBIT
$-14.6m | $-21.5m
Net Income
$-14.0m | $-19.1m
Free Cash Flow
$-14.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
40.2% | -
EBIT
40.2% | 2.2%
Net Income
-323.9% | -1,427.1%
Free Cash Flow
30.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.9
FCF per Share
$-2.0
Short interest
9.5%
Employees
8
Rev per Employee
$0.0
Show more

Is Minerva Neurosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Minerva Neurosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Minerva Neurosciences Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Minerva Neurosciences Inc forecast:

Hold
50%
Sell
50%

Financial data from Minerva Neurosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.07 9.07
8% 8%
-
- Research and Development Expense 5.57 5.57
62% 62%
-
-15 -15
40% 40%
-
- Depreciation and Amortization 0.01 0.01
67% 67%
-
EBIT (Operating Income) EBIT -15 -15
40% 40%
-
Net Profit -14 -14
324% 324%
-

In millions USD.

Don't miss a Thing! We will send you all news about Minerva Neurosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Minerva Neurosciences Inc Stock News

Neutral
GlobeNewsWire
15 days ago
Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will also serve as a consultant for roluperidone development.
Neutral
GlobeNewsWire
29 days ago
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025.
Neutral
GlobeNewsWire
about one month ago
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone's clinical development and NDA resubmission.
More Minerva Neurosciences Inc News

Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO Rémy Luthringer
Employees 8
Founded 2007
Website www.minervaneurosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today